中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2014, Vol. 49 Issue (13) :1093-1098    DOI: 10.11669/cpj.2014.13.001
���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
��������ص�ҩ�����ü�Ӧ���о���չ
Ф����1��2����ƽ��1��������1�����¿�1������ɽ1*
1.ɽ����ѧҩѧԺ������ 250012��
2.̩ɽҽѧԺҩѧԺ��̩�� 271002
XIAO Yu-liang1,2, LI Ping-li1,CHENG Yan-na1, ZHANG Xin-ke1,WANG Feng-shan1*
1.School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China;
2.College of Pharmaceutical Sciences, Taishan Medical University, Taian 271002, China

Download: PDF (1102KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� ������������������ص�ҩ�����ü�Ӧ���о���չ������ ���ݹ�����������ף�����������ص�ҩ�����ü�Ӧ�ý����������ܽᡣ�������� ��������ؾ��п��ס����ߵ��ڡ�����Ѫ�ܱ������񾭱�������������ϸ��𤸽���ڡ��������ȶ���ҩ��ѧ���ԣ�Ŀǰ�ٴ�����Ҫ���ڹǹؽ��ס�����Ѫ�ܼ������ۿƼ�����Ԥ�������ƣ��ҳ��ڷ��ö�������С���Ǻ��п���DZ����ҩ�
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
����
��ƽ��
������
���¿�
����ɽ*
�ؼ����� ���������   ����   ���ߵ���   ����Ѫ�ܱ���     
Abstract�� OBJECTIVE To review the pharmacologic action and application of chondroitin sulfate.METHODS The pharmacologic action and application of chondroitin sulfate are reviewed based on the relevant articles published in recent years.RESULTS AND CONCLUSION Chondroitin sulfate has been demonstrated to possess varieties of pharmacological activities, including anti-inflammation,immunoregulation, anti-atherosclerosis, anti-oxidation, regulating cell adhesion and anti-tumor. So far, it is mainly used to prevent and treat osteoarthritis, cardiovascular and cerebrovascular diseases, as well as ophthalmological diseases in clinic with good tolerability and safety. Therefore, chondroitin sulfate is a drug with great development potential.
Keywords�� chondroitin sulfate,   anti-inflammation,   immunoregulation,   anti-atherosclerosis     
�ո�����: 2014-09-03;
��������:ɽ��ʡ��Ȼ�����У�����е�λ����ר��(ZR2011HL052)��ɽ��ʡ̩ɽѧ��ҩѧ��Ƹר�Ҽƻ�������Ŀ
ͨѶ���� ����ɽ,��,����,��ʿ����ʦ �о�����:���������\��ҩ��Tel/Fax:(0531)88380288     Email: fswang@sdu.edu.cn
���߼��: Ф�������У���ʿ�о����о�����:����ҩ��
���ñ���:   
Ф����, , ��ƽ���� .��������ص�ҩ�����ü�Ӧ���о���չ[J]  �й�ҩѧ��־, 2014,V49(13): 1093-1098
XIAO Yu-Liang-, , LI Ping-Li- etc .Progress in the Study of Pharmacology and Application of Chondroitin Sulfate[J]  Chinese Pharmaceutical Journal, 2014,V49(13): 1093-1098
��
[1] UEBELHART D, MALAISE M, MARCOLONGO R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage, 2004,12(4):269-276.[2] CLEGG D O, REDA D J, HARRIS C L, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med, 2006,354(8):795-808.[3] MARTIN M S, VAN SELL S, DANTER J. Glucosamine and chondroitin: An appropriate adjunct treatment of symptomatic osteoarthritis of the knee. Orthop Nurs, 2012,31(3):160-166.[4] REGINSTER J Y. In people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo.Evid Based Med, 2012,17(5):152-153.[5] DOMAGALA F, MARTIN G, BOGDANOWICZ P, et al. Inhibition of interleukin-1��-induced activation of MEK/ERK pathway and DNA binding of NF-��B and AP-1: Potential mechanism for Diacerein effects in osteoarthritis. Biorheology, 2006,43(3):577-587.[6] DU SOUICH P, GARCIA A G, VERGES J, et al. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med, 2009,13(8):1451-1463.[7] HE Z X, JIN Y, ZHANG T M. Structure of chondroitin sulfate and its application in osteoarthritis therapy .Chin Pharm J(�й�ҩѧ��־),2012,47(5): 387-391.[8] MCALINDON T E, LAVALLEY M P, GULIN J P, et al. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA, 2000,283(11): 1469-1475.[9] GABAY C, MEDINGER-SADOWSKI C, GASCON D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: A randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum, 2011,63(11):3383-3391. RUBIO-TERRES C. An economic evaluation of chondroitin sulfate and non-steroidal anti-inflammatory drugs for the treatment of osteoarthritis. Data from the VECTRA study. Reumatol Clin, 2010,6(4):187-195. IAVAZZO C, ATHANASIOU S, PITSOUNI E, et al. Hyaluronic acid: An effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis. Eur Urol, 2007,51(6):1534-1540. DAMIANO R, CICIONE A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol, 2011, 3(5):223-232. CERVIGNI M, NATALE F, NASTA L, et al. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct, 2008,19(7):943-947. CERVIGNI M, NATALE F, NASTA L, et al. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: Long-term treatment results.Int Urogynecol J, 2012,23(9):1187-1192. DAMIANO R, QUARTO G, BAVA I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: A placebo-controlled randomisedtrial. Eur Urol, 2011, 59(4):645-651. ZHANG G R, ZHANG C H, LIU A J, et al. Influence of cartilage polysaccharide on humoral immunity function of tumor-bearing mice.Mod Food Sci Tech(�ִ�ʳƷ�Ƽ�), 2009, 25(5):466-468. SAKAI S, AKIYAMA H, SATO Y, et al. Chondroitin sulfate intake inhibits the IgE-mediated allergic response by down-regulating Th2 responses in mice. J Biol Chem, 2006,281(29): 19872-19880. AKIYAMA H, SAKAI S, LINHARDT R J, et al. Chondroitin sulphate structure affects its immunological activities on murine splenocytes sensitized with ovalbumin.Biochem J, 2004,382(Pt 1):269-278. MOLLER I, PEREZ M, MONFORT J, et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: A randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage, 2010, 18 (1):32-40. VERG��S J, MONTELL E, HERRERO M, et al. Clinical and histopathological improvement of psoriasis in patients with osteoarthritis treated with chondroitin sulfate: Report of 3 cases. Medicinacl��nica, 2004,123(19):739-742. VERGES J, MONTELL E, HERRERO M, et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: A serendipitous finding.Dermatol Online J, 2005,11(1):31. MAKSIMENKO A V, GOLUBYKH V L, TISCHENKO E G. Catalase and chondroitin sulfate derivatives against thrombotic effect induced by reactive oxygen species in a rat artery. Metab Eng, 2003,5(3):177-182. MOURAO P A, BOISSON-VIDAL C, TAPON-BRETAUDIERE J, et al. Inactivation of thrombin by a fucosylated chondroitin sulfate from echinoderm. Thromb Res, 2001,102(2):167-176. FONSECA R J, MOURAO P A. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Thromb Haemost, 2006,96(6):822-929. KAPLAN M, AVIRAM M. Macrophage plasma membrane chondroitin sulfate proteoglycan binds oxidized low-density lipoprotein. Atherosclerosis, 2000, 149(1):5-17. YAO X Y. Study on lipid-decreasing effect of chondroitin sulfate polysaccharides from monopterusalbus bone.China Med Rep(�й�ҽҩ����), 2011,8(30):31-33. HAN L K, SUMIYOSHI M, TAKEDA T, et al. Inhibitory effects of chondroitin sulfate prepared from salmon nasal cartilage on fat storage in mice fed a high-fat diet. Int J Obes Relat Metab Disord, 2000,24(9):1131-1138. KURITA H. ��ber den einfluss des chon-droitin sulfates auf die experimentelle ath-erosklerose in kaninchen. Med J Shinshu Univ, 1955,1:23-27. GUTIERREZ S H, KURI M R, DEL CASTILLO E R. Cardiac role of the transcription factor NF-kappaB. Cardiovasc Hematol Disord Drug Targets, 2008,8(2):153-160. TAT S K, PELLETIER J P, VERG��S J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: A basic science study. Arthritis Research and Therapy, 2007,9(6):117. OLSSON U, OSTERGREN-LUNDEN G, MOSES J. Glycosaminoglycan-lipoprotein interaction. Glycoconj J, 2001,18(10):789-797. JOMPHE C, GABRIAC M, HALE T M, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol, 2008, 102(1):59-65. HERRERO-BEAUMONT G, MARCOS M E, SANCHEZ-PERNAUTE O, et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol, 2008,154(4):843-851. SUGAHARA K, MIKAMI T. Chondroitin/dermatan sulfate in the central nervous system. Curr Opin Struct Biol, 2007,17(5):536-545. RHODES K E, FAWCETT J W. Chondroitin sulphate proteoglycans: Preventing plasticity or protecting the CNS?. J Anat, 2004,204(1):33-48. ROLLS A, SHECHTER R, LONDON A, et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: A role in microglia/macrophage activation. PLoS Med, 2008,5(8):171. ROLLS A, AVIDAN H, CAHALON L, et al. A disaccharide derived from chondroitin sulphate proteoglycan promotes central nervous system repair in rats and mice. Eur J Neurosci, 2004,20(8):1973-1983. ROLLS A, CAHALON L, BAKALASH S, et al. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. FASEB J, 2006,20(3):547-549. CANAS N, VALERO T, VILLARROYA M, et al. Chondroitin sulfate protects SH-SY5Y cells from oxidative stress by inducing heme oxygenase-1 via phosphatidylinositol 3-kinase/Akt. J Pharmacol Exp Ther, 2007,323(3):946-953. EGEA J, GARCIA A G, VERGES J, et al. Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans. Osteoarthritis Cartilage, 2010,18(1):24-27. MULLER A J, LETELIER M E, GALLEGUILLOS M A, et al. Comparison of the antioxidant effects of synovial fluid from equine metacarpophalangeal joints with those of hyaluronic acid and chondroitin sulfate. Am J Vet Res, 2010,71(4):399-404. LEE J Y, LEE S H, KIM H J, et al. The preventive inhibition of chondroitin sulfate against the CCl4-induced oxidative stress of subcellular level. Arch Pharm Res, 2004,27(3):340-345. CAMPO G M, AVENOSO A, CAMPO S, et al. Chondroitin-4-sulphate reduced oxidative injury in caerulein-induced pancreatitis in mice: The involvement of NF-kappaB translocation and apoptosis activation. Exp Biol Med (Maywood), 2008,233(6):741-752. CAMPO G M, AVENOSO A, CAMPO S, et al. The antioxidant activity of chondroitin-4-sulphate, in carbon tetrachloride-induced acute hepatitis in mice, involves NF-kappaB and caspaseactivation. Br J Pharmacol, 2008,155(6):945-956. ASIMAKOPOULOU A P, THEOCHARIS A D, TZANAKAKIS G N, et al. The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo, 2008,22(3): 385-389. MONFORT J, NACHER M, MONTELL E, et al. Chondroitin sulfate and hyaluronic acid (500-730 kda) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Under Exp Clin Res, 2005,31(2):71-76. PUMPHREY C Y, THEUS A M, LI S, et al. Neoglycans, carbodiimide-modified glycosaminoglycans: A new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res, 2002,62(13):3722-3728. LIN H. Study on the Anti-Inflammatory and Anti-Tumor Effects of Shark Chondroitin Sulfate and Its Supersulfated Derivatives. Jinan:Shandong University, 2006. LIU K W, CHI Y,LV J. Therapeutic efficacy of shark chondroitin combined with chemotherapy in treatment of advanced non-small cell lung cancer.Chin J Clin Oncol Rehabil(�й������ٴ��뿵��), 2009,16(2):167-169. BEESON J G, ANDREWS K T, BOYLE M, et al. Structural basis for binding of plasmodium falciparum erythrocyte membrane protein 1 to chondroitin sulfate and placental tissue and the influence of protein polymorphisms on binding specificity. J Biol Chem, 2007,282(31): 22426-224236. BERGEFALL K, TRYBALA E, JOHANSSON M, et al. Chondroitin sulfate characterized by the E-disaccharide unit is a potent inhibitor of herpes simplex virus infectivity and provides the virus binding sites on gro2C cells. J Biol Chem, 2005,280(37):32193-32199. LAI J Y, LI Y T, CHO C H, et al. Nanoscale modification of porous gelatin scaffolds with chondroitin sulfate for corneal stromal tissue engineering.Int J Nanomedicine, 2012,7:1101-1114. FAN W X, MA X H, GE D, et al. Cryoprotectants for the vitrification of corneal endothelial cells. Cryobiology, 2009,58(1):28-36. KOBAYASHI F, YAMADA S, TAGUWA S, et al. Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus. Glycoconj J, 2012,29(4):211-220.
[1] ����, ��, �����, ����, ������*.��Ч������ɸѡ�ߵ���Ƥ�ڷ�Һ����ƽ��ҩЧ�ɷ�[J]. �й�ҩѧ��־, 2014,49(6): 459-463
[2] ��ѧ��, ���ӻ�, ����, ���, ȫ����*.�����ز�ͬ�ܼ���ȡ��Զ������������յ���С���Ը����˵ı�������[J]. �й�ҩѧ��־, 2014,49(6): 469-472
[3] �̺���, �����*.�������࿹��ҩ����Ѫ�ܼ��������еĺ���ʹ��[J]. �й�ҩѧ��־, 2014,49(6): 512-516
[4] Ѧ����, �ϼ *, �ܻ�ʫ.���������ҩ�ﺬ���ⶨ�����о���չ[J]. �й�ҩѧ��־, 2014,49(4): 271-274
[5] ��ѩ��, ������*.�������ֲ����ܻ�ͪ�����������Էβ�����ģ����֢�ĸ�Ԥ���ü������о�[J]. �й�ҩѧ��־, 2014,49(4): 294-297
[6] ����,��Ƽ,�����,���ű�,���*.̪ݼ����ӫ��̽�������ӱ�����Լ���ϵ������ӫ����ǿ���ⶨ��������ص��о�[J]. �й�ҩѧ��־, 2014,49(10): 890-895
[7] Ѧǿ������������������ɭ�룬������*.��ձë�̶���С�����ߵ��ڼ������˱��������о�[J]. �й�ҩѧ��־, 2013,48(8): 601-605
[8] ��ε��,�����,����,������*.��׼�������͵Ŀ��������о�[J]. �й�ҩѧ��־, 2013,48(5): 349-353
[9] ������, ����*.��������࿹����ʹֹ�������о�[J]. �й�ҩѧ��־, 2013,48(4): 266-268
[10] ����ӱ���κ��񣬴޿�.3-����-6-�����������ͪ�ĺϳɼ�������ʹ�����о�[J]. �й�ҩѧ��־, 2013,48(3): 224-227
[11] ���޻�,�,������,��Ρ��,�º���,����.ά�������Ŀ�����ʹ�����о�[J]. �й�ҩѧ��־, 2013,48(20): 1736-1739
[12] ��ƽ��֣���ƣ������.���踴�����Դ�����ȱѪ�����������������񾭽���������������ص��׶��DZ�����������[J]. �й�ҩѧ��־, 2013,48(15): 1279-1283
[13] �»���������*���Գ��������֣�������.�����ݿ��׻��Բ�λ��Ч��ϵ����ЧҺ��ɫ��-Ч��ϵ�о�[J]. �й�ҩѧ��־, 2013,48(14): 1190-1193
[14] ����,����,�*.Ӧ��3T3ϸ���ⶾ��ʵ�����ۼ��ַ����忹��ҩ�Ĺⶾ��[J]. �й�ҩѧ��־, 2013,48(11): 912-915
[15] ��⣬������*���Źڻ�*.��޲�ҩ�����ü��ٴ�Ӧ���о���չ[J]. �й�ҩѧ��־, 2013,48(11): 949-952
Copyright 2010 by �й�ҩѧ��־